This pilot study looked to determine the efficacy and safety of intravaginal DHEA in a group of 12 female patients with low-grade cervical dysplasia. DHEA was administered as a 150mg daily dose for a period of up to 6 months. Cervical follow-up evaluations were carried out at 3 and 6 months from starting the DHEA treatment. At the end of the study 83% of the women were found to have no evidence of dysplasia and no serious side effects were reported. Overall, the researchers concluded that intravaginal DHEA was safe and well tolerated by all participants of the study, and that use of DHEA may promote regression of low-grade cervical lesions.
